Pharmacotherapy for the prevention of post-ERCP pancreatitis

Erina Foster, Joseph Leung

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

Original languageEnglish (US)
Pages (from-to)52-55
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume102
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Endoscopic Retrograde Cholangiopancreatography
Pancreatitis
Drug Therapy
Drug Administration Routes
Pressure
Pancreas

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pharmacotherapy for the prevention of post-ERCP pancreatitis. / Foster, Erina; Leung, Joseph.

In: American Journal of Gastroenterology, Vol. 102, No. 1, 01.2007, p. 52-55.

Research output: Contribution to journalArticle

@article{4581fd6a685c43248fe5b717b3c67aa8,
title = "Pharmacotherapy for the prevention of post-ERCP pancreatitis",
abstract = "Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.",
author = "Erina Foster and Joseph Leung",
year = "2007",
month = "1",
doi = "10.1111/j.1572-0241.2006.00950.x",
language = "English (US)",
volume = "102",
pages = "52--55",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pharmacotherapy for the prevention of post-ERCP pancreatitis

AU - Foster, Erina

AU - Leung, Joseph

PY - 2007/1

Y1 - 2007/1

N2 - Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

AB - Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=33846063359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846063359&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.00950.x

DO - 10.1111/j.1572-0241.2006.00950.x

M3 - Article

C2 - 17266688

AN - SCOPUS:33846063359

VL - 102

SP - 52

EP - 55

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 1

ER -